depend
host
interact
hundr
extracellular
protein
cell
surfac
glycosaminoglycan
heparan
sulphat
hs
regul
homeostasi
exploit
mani
microbi
pathogen
mean
adher
invas
close
relat
polysaccharid
heparin
wide
use
anticoagul
drug
structur
similar
hs
common
experiment
proxi
expect
mimic
properti
hs
heparin
prevent
infect
rang
virus
ad
exogen
includ
sassoci
coronaviru
strain
show
addit
heparin
vero
cell
inhibit
invas
also
demonstr
heparin
bind
spike
protein
receptor
bind
domain
induc
conform
chang
illustr
surfac
plasmon
reson
circular
dichroism
spectroscopi
studi
structur
featur
heparin
interact
depend
investig
use
librari
heparin
deriv
sizedefin
fragment
bind
strongli
depend
presenc
sulphat
consequ
conform
consequ
heparin
structur
nsulphat
hexasaccharid
requir
conform
chang
induc
secondari
structur
compar
aris
heparin
bind
enoxaparin
low
molecular
weight
clinic
anticoagul
also
bind
rbd
protein
induc
conform
chang
find
implic
rapid
develop
firstlin
therapeut
repurpos
heparin
well
nextgener
tailormad
gagbas
antivir
agent
member
coronavirida
heparin
second
wide
use
drug
weight
global
formul
polydispers
heterogen
natur
product
unfraction
heparin
low
molecular
weight
heparin
enoxaparin
heparinoid
clinic
approv
anticoagul
antithrombot
agent
excel
safeti
stabil
bioavail
pharmacokinet
profil
crucial
heparin
deriv
lack
signific
anticoagul
activ
constitut
underexploit
antivir
drug
class
despit
fact
exhibit
broadspectrum
activ
numer
distinct
virus
includ
coronavirida
sarsassoci
coronaviru
strain
addit
flavivirus
herp
influenza
hiv
convent
drug
develop
process
slow
respond
emerg
public
health
threat
current
coronaviru
outbreak
make
repurpos
exist
drug
time
attract
altern
heparin
welltoler
anticoagul
pharmaceut
use
safe
medicin
year
alongsid
anticoagul
activ
abil
prevent
viral
infect
includ
member
coronavirida
describ
close
relat
glycosaminoglycan
gag
member
heparan
sulphat
hs
also
known
bind
cov
surfac
protein
exploit
coronaviru
attach
target
cell
furthermor
anticoagul
antiinflammatori
therapi
associ
heparin
use
shown
benefici
manag
heparan
sulphat
ubiquit
compon
cell
surfac
extracellular
matrix
complex
nontempl
driven
biosynthesi
involv
mani
enzym
consequ
heterogen
structur
current
hs
heparin
known
bind
protein
heparan
sulphat
heparin
linear
sulphat
polysaccharid
compris
repeat
disaccharid
unit
uron
acid
dglucosamin
link
glycosid
bond
uron
acid
either
dglucuron
acid
epim
liduron
acid
properli
glucuron
iduron
respect
physiolog
condit
disaccharid
subject
sever
modif
iduron
osulph
glucosamin
nsulphat
nacetyl
unmodifi
adorn
osulph
less
frequent
anticoagul
properti
heparin
aris
predominantli
interact
serin
proteas
particularli
antithrombin
pentasaccharid
sequenc
identifi
signific
regard
hand
antivir
antiinflammatori
properti
link
specif
sequenc
enabl
strategi
develop
product
heparin
tailor
activ
ie
nonanticoagul
antivir
involv
cleavingdisrupt
chain
antithrombin
interact
pentasaccharid
global
alter
chemic
properti
chain
sinc
heparin
complex
mixtur
contain
polysaccharid
chain
vari
composit
bear
differ
biolog
activ
altern
approach
would
fraction
heterogen
heparin
mixtur
isol
fraction
requir
activ
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
yet
commerci
avail
medicin
product
design
treat
andor
prevent
infect
associ
current
coronaviru
outbreak
describ
abil
heparin
inhibit
cell
invas
bind
receptor
bind
domain
rbd
investig
structur
requir
consequ
bind
result
underpin
develop
heparinbas
therapeut
futur
viral
diseas
vero
cell
ecacc
plate
x
cell
per
well
plate
incub
emem
supplement
vv
foetal
calf
serum
complet
medium
twenti
four
hour
later
cell
incub
heparin
celsu
laboratori
cincinnati
usa
complet
medium
hour
prior
infect
incub
viru
solut
contain
plaqu
form
unit
pfu
either
strain
gisaid
access
id
sarscov
eid
incub
hour
supernat
discard
wv
methylcellulos
sigmaaldrich
itali
overlay
complet
medium
ad
well
day
cell
fix
use
vv
formaldehyd
phosphatebuff
salin
solut
stain
wv
crystal
violet
sigmaaldrich
itali
vv
methanol
sigmaaldrich
itali
plaqu
count
stereoscop
microscop
nikon
residu
spike
protein
genbank
clone
upstream
ntermin
prseta
express
vector
transform
express
compet
e
coli
neb
uk
protein
express
carri
e
coli
express
media
invitrogen
uk
hr
rpm
bacteri
pellet
suspend
ml
lysi
buffer
bugbust
protein
extract
reagent
merck
millipor
uk
contain
dnase
incub
room
temperatur
min
protein
purifi
inclus
bodi
use
imac
chromatographi
denatur
condit
oncolumn
protein
refold
perform
appli
gradient
decreas
concentr
denatur
agent
urea
extens
wash
protein
elut
use
mm
ph
mm
nacl
mm
imidazol
fraction
pool
bufferexchang
phosphatebuff
salin
pb
mm
nacl
mm
mm
ph
lonza
uk
use
sephadex
column
ge
healthcar
uk
recombin
protein
store
requir
chemic
modifi
heparin
polysaccharid
tabl
synthesis
parent
unfraction
porcin
mucos
heparin
mw
kda
celsu
laboratori
cincinnati
usa
previous
describ
verac
chemic
modif
ascertain
use
h
c
nmr
chemic
shift
compar
tsp
sigmaaldrich
uk
extern
refer
standard
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
secondari
structur
determin
rbd
circular
dichroism
spectroscopi
circular
dichroism
cd
spectrum
rbd
pb
record
use
jasco
cd
spectromet
jasco
uk
spectral
manag
ii
softwar
jasco
uk
mm
pathlength
quartz
cuvett
hellma
usa
scan
nmmin
nm
resolut
throughout
rang
nm
spectra
obtain
mean
five
independ
scan
follow
instrument
calibr
camphorsulfon
acid
rbd
bufferexchang
prior
spectral
analysi
use
kda
vivaspin
centrifug
filter
sartoriu
germani
g
thrice
cd
spectra
collect
use
mgml
solut
pb
ph
spectra
heparin
porcin
mucos
heparin
deriv
oligosaccharid
collect
buffer
approxim
compar
concentr
sinc
dispers
materi
collect
data
analys
spectral
manag
ii
softwar
prior
process
graphpad
prism
use
second
order
polynomi
smooth
neighbour
secondari
structur
predict
calcul
use
bestsel
analysi
server
micsonai
ensur
cd
spectral
chang
rbd
presenc
porcin
mucos
heparin
aris
addit
heparin
alon
known
possess
cd
spectrum
high
concentr
differ
spectrum
analys
theoret
cd
spectrum
result
arithmet
addit
cd
spectrum
rbd
heparin
differ
observ
experiment
cd
spectrum
rbd
mix
heparin
demonstr
chang
cd
spectrum
aros
conform
chang
follow
bind
porcin
mucos
heparin
reson
determin
rbd
bind
unfraction
heparin
human
produc
describ
duchesn
et
al
duchesn
porcin
mucos
heparin
biotinyl
reduc
end
use
hydroxylamin
biotin
thermofish
uk
describ
thakar
et
al
heparin
mg
ml
react
hydroxylaminebiotin
mm
anilin
sigmaaldrich
uk
mm
acet
ph
h
free
biotin
remov
gelfiltr
chromatographi
sephadex
ge
lifesci
uk
multichannel
surfac
plasmon
reson
spr
instrument
instrument
canada
employ
gold
sensor
chip
plasma
clean
prior
derivat
selfassembl
monolay
mpeg
thiol
biotin
mpeg
form
incub
chip
mm
solut
reagent
molar
ratio
ethanol
hr
chip
rins
ethanol
place
instrument
pb
use
run
buffer
three
sens
fourth
background
channel
use
ismatec
pump
twenti
microgram
streptavidin
sigma
uk
ml
pb
inject
four
sensor
channel
subsequ
biotinheparin
ml
inject
three
sens
channel
bind
experi
use
pb
tween
vv
run
buffer
ligand
inject
three
sens
channel
dilut
concentr
indic
figur
legend
sensor
surfac
bound
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
regener
wash
nacl
fisher
scientif
uk
howev
found
ineffectu
rbd
partial
regener
surfac
achiev
mm
hcl
vwr
uk
wv
sd
vwr
uk
found
remov
bound
protein
regener
wv
sd
fluidic
surfac
wash
mm
hcl
ensur
trace
deterg
remov
background
bind
underli
streptavidin
bound
mpegbiotin
mpeg
selfassembl
monolay
determin
inject
control
channel
respons
report
chang
plasmon
reson
wavelength
nm
three
control
channel
repres
averag
respons
method
employ
predict
heparin
bind
sequenc
within
rbd
describ
rudd
et
al
brief
descript
method
follow
combin
ori
et
al
nune
et
al
identifi
heparin
bind
protein
studi
heparin
bind
protein
previous
identifi
list
decompos
amino
acid
sequenc
contain
less
residu
less
one
basic
amino
acid
simplifi
problem
heparin
bind
protein
fragment
sequenc
contain
follow
combin
amino
acid
bx
bxa
bx
bxp
bxa
bxap
bxp
b
basic
x
hydrophob
acid
p
polar
special
sequenc
compar
use
metric
base
levenshtein
distanc
measur
similar
string
charact
defin
minimum
number
insert
delet
substitut
need
appli
charact
alter
one
sequenc
match
sequenc
similar
score
greater
similar
consid
highli
conserv
set
highli
conserv
basic
amino
acid
contain
sequenc
found
heparin
bind
protein
use
identifi
possibl
heparin
bind
sequenc
within
util
levenshtein
similar
cutoff
progeni
infecti
virion
product
measur
cultur
supernat
use
standard
plaqu
form
assay
vero
cell
without
pretreat
incub
heparin
one
hour
prior
infect
histor
sarscov
strain
recent
strain
signific
decreas
observ
number
pfu
upon
heparin
treatment
sarscov
later
demonstr
significantli
higher
level
inhibit
compar
sarscov
figur
wellcharacteris
heparinbind
protein
use
confirm
success
function
three
sens
channel
biotinheparin
inject
ml
nm
sens
channel
elicit
signific
respons
figur
inject
blue
red
arrow
howev
nm
elicit
respons
control
channel
function
sole
streptavidin
figur
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
bound
remov
wash
nacl
previous
iasi
optic
biosensor
nm
rbd
inject
three
sens
channel
increas
signal
bind
figur
inject
start
blue
arrow
end
inject
system
return
run
buffer
pbst
red
arrow
dissoci
common
surfac
measur
particularli
flow
system
due
extens
boundari
layer
liquid
enabl
rebind
analyt
often
caus
substanti
underestim
dissoci
rate
koff
remedi
addit
solubl
ligand
inject
nm
rbd
control
channel
functionalis
streptavidin
show
small
increas
respons
figur
order
seen
measur
channel
repeat
measur
indic
maximum
level
background
bind
data
demonstr
nm
rbd
bind
specif
heparin
immobilis
reduc
end
interact
major
extent
underli
streptavidinethyleneglycol
surfac
note
biotinheparin
anchor
streptavidin
layer
measur
channel
background
bind
reduc
sinc
less
underli
surfac
expos
illustr
competit
experi
solubl
heparin
abl
complet
abrog
bind
rbd
surfac
figur
first
set
competit
experi
immobilis
nm
rbd
expos
heparin
enoxaparin
indic
concentr
respons
surfac
return
run
buffer
pbst
measur
appropri
sinc
appreci
dissoci
heparinbound
rbd
surfac
return
pbst
figur
ensur
differ
refract
index
sampl
interfer
measur
mgml
heparin
small
reduct
bind
rbd
observ
figur
concentr
heparin
increas
bind
rbd
decreas
dosedepend
manner
rbd
bind
complet
abrog
mgml
heparin
enoxaparin
also
found
inhibit
bind
rbd
weight
basi
less
potent
heparin
figur
thu
small
inhibit
bind
observ
mgml
enoxaparin
maxim
inhibit
observ
polysaccharid
mgml
data
indic
heparin
potent
inhibitor
interact
rbd
immobilis
heparin
enoxaparin
examin
whether
short
oligosaccharid
could
inhibit
rbd
bind
heparinderiv
octasaccharid
dp
without
effect
decasaccharid
mgml
show
modest
inhibit
rbd
bind
immobilis
heparin
whether
data
reflect
true
requir
longer
structur
rbd
bind
instead
reflect
select
reduct
presenc
particular
bind
structur
polysaccharid
consequ
process
enoxaparin
partial
enzymat
heparin
degrad
oligosaccharid
remain
determin
next
test
abil
librari
heparin
select
modifi
tabl
inhibit
rbd
bind
show
differ
level
inhibitori
activ
depend
pattern
sulphat
singli
desulph
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
heparin
heparin
ndesulphatednreacetyl
show
inhibitori
activ
mgml
mgml
wherea
heparin
heparin
desulph
respect
detect
inhibitori
activ
figur
suggest
rbd
prefer
tract
saccharid
sulphat
interestingli
doubli
desulph
heparin
heparin
heparin
heparin
possess
inhibitori
activ
albeit
lower
nativ
heparin
figur
sinc
sulphat
polysaccharid
mark
effect
conform
data
suggest
rbd
may
prefer
particular
spatial
arrang
charg
group
complet
desulph
heparin
heparin
inhibitori
activ
indic
ionic
interact
sulphat
group
make
import
contribut
interact
rbd
polysaccharid
persulph
heparin
heparin
inhibit
strongli
heparin
deriv
effect
nativ
heparin
indic
like
import
conform
polysaccharid
rbd
bind
sinc
sulphat
avail
hydroxyl
render
polysaccharid
rigid
restrict
conform
flexibl
circular
dichroism
cd
spectroscopi
far
uv
region
nm
detect
conform
chang
protein
secondari
structur
occur
solut
infer
bind
ad
ligand
secondari
structur
chang
quantifi
use
spectral
deconvolut
rbd
underw
conform
chang
presenc
heparin
figur
consist
increas
content
decreas
global
observ
chang
demonstr
rbd
interact
heparin
aqueou
condit
physiolog
relev
chemic
modifi
heparin
deriv
predomin
repeat
disaccharid
structur
abl
induc
close
compar
secondari
structur
chang
rbd
heparin
figur
c
analysi
cd
spectroscopi
role
chain
length
heparinderiv
oligosaccharid
figur
reveal
hexasaccharid
fraction
abl
induc
similar
conform
chang
heparin
basic
amino
acid
known
domin
bind
protein
heparin
mind
primari
sequenc
analysi
express
protein
domain
analysi
model
rbd
structur
figur
conduct
indic
sever
potenti
heparin
bind
site
importantli
patch
basic
amino
acid
expos
protein
surfac
analysi
rbd
sequenc
potenti
heparin
bind
site
employ
metric
base
levenshtein
distanc
measur
similar
two
sequenc
found
basic
amino
acid
sequenc
within
rbd
similar
sequenc
found
heparin
bind
protein
predict
heparin
bind
basic
amino
acid
contain
sequenc
shown
tabl
basic
amino
acid
normalis
count
greater
found
rkr
lvk
kk
r
also
number
possibl
secondari
site
interact
normalis
count
great
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
r
r
k
h
one
consequ
abil
rbd
interact
hs
provid
rout
adher
cell
surfac
enabl
invas
convers
region
also
interact
orthodox
receptor
spike
protein
rbd
suggest
heparin
deriv
interfer
interact
viru
via
residu
furthermor
identifi
sequenc
except
tkln
gkiadynyklp
pyrvvvl
expos
protein
surfac
avail
bind
studi
spike
protein
structur
behaviour
solut
import
step
develop
effect
therapeut
abil
rbd
bind
pharmaceut
heparin
studi
use
spectroscop
techniqu
show
rbd
bind
heparin
upon
bind
signific
conform
chang
induc
moreov
moieti
basic
amino
acid
residu
common
constitu
heparin
bind
domain
access
solvent
rbd
surfac
form
continu
patch
figur
suitabl
heparin
bind
comparison
rbd
amino
acid
sequenc
residu
extens
librari
sequenc
known
heparin
bind
protein
tabl
base
levenstein
distanc
provid
measur
degre
similar
sequenc
suggest
wider
area
rbd
surfac
may
avail
figur
bind
host
cell
surfac
glycosaminoglycan
polysaccharid
may
relat
propens
viru
select
particular
speci
individu
age
group
sinc
gag
composit
known
vari
evid
potenti
heparinbind
gain
function
mutat
figur
rapid
spread
repres
signific
challeng
global
health
author
sinc
current
approv
drug
treat
prevent
andor
mitig
effect
repurpos
exist
drug
time
appeal
strategi
heparin
welltoler
anticoagul
drug
use
success
year
limit
manag
side
effect
furthermor
heparin
belong
uniqu
class
pharmaceut
effect
antidot
avail
make
safer
use
glycosaminoglycan
present
almost
mammalian
cell
class
carbohydr
central
strategi
employ
coronavirida
attach
host
cell
heparin
previous
shown
inhibit
sarsassoci
coronaviru
strain
cell
invas
potenti
repres
attract
possibl
observ
heparin
abl
inhibit
invas
vero
cell
signific
find
offer
one
potenti
rout
prophylaxi
well
highlight
capac
class
biolog
macromolecul
interven
microbi
particularli
viral
infect
abil
addit
use
properti
anticoagul
moder
inflamm
remain
understudi
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
underexploit
offer
potenti
intervent
mani
microbi
interact
least
relat
emerg
viral
diseas
depend
particular
structur
featur
heparin
scaffold
result
chang
conform
spike
protein
rbd
predict
heparinbind
featur
provid
evid
interact
heparin
involv
level
structur
specif
also
suggest
heparin
complex
mixtur
polysaccharid
contain
rang
activ
potenti
separ
without
modif
provid
divers
deriv
provid
rang
properti
tailor
suit
varieti
clinic
circumst
heparin
deriv
amen
routin
parenter
administr
current
establish
rout
addit
directli
respiratori
tract
via
nasal
administr
use
nebulis
heparin
would
unlik
gain
signific
access
circul
thu
anticoagul
activ
heparin
event
engin
suitabl
chemic
modif
would
pose
problem
importantli
rout
administr
would
suitabl
prophylaxi
also
patient
mechan
ventil
togeth
data
support
use
gagderiv
pharmaceut
sarsassoci
coronaviru
furthermor
studi
support
repurpos
heparin
deriv
antivir
agent
provid
rapid
countermeasur
current
outbreak
futur
emerg
viral
diseas
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
figur
effect
unfraction
porcin
mucos
heparin
ad
one
hour
infect
vero
cell
pfu
sarscov
nil
repres
treatment
result
express
number
pfu
per
well
repres
mean
sd
quadrupl
cultur
p
valu
calcul
use
mannwhitney
u
test
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
competit
rbd
bind
immobilis
heparin
model
heparinderiv
oligoand
polysaccharid
nm
rbd
inject
onto
surfac
presenc
absenc
indic
concentr
heparinderiv
oligoand
polysaccharid
sinc
rbd
dissoci
appreci
system
return
pbst
respons
measur
avoid
confound
effect
differ
refract
index
sampl
control
measur
nm
rbd
alon
perform
competit
use
calcul
percentag
maximum
bind
ensur
small
chang
time
respons
surfac
cofound
analysi
competit
nm
rbd
bind
immobilis
heparin
heparin
enoxaparin
b
competit
nm
rbd
bind
immobilis
heparin
mgml
heparinderiv
dp
dp
correspond
valu
heparin
panel
shown
aid
comparison
c
competit
nm
rbd
bind
immobilis
heparin
panel
orthogon
chemic
desulph
heparin
tabl
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
rbd
protein
model
basic
amino
acid
solvent
access
surfac
indic
dark
blue
form
extens
patch
sequenc
highest
normalis
count
tabl
highlight
also
shown
indic
potenti
heparinbind
gain
function
mutat
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
tabl
tabl
repeat
structur
heparin
deriv
addit
osulph
posit
glucosamin
uron
acid
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
tabl
tabl
sequenc
analysi
rbd
amino
acid
sequenc
number
normal
count
similar
sequenc
rbd
found
librari
heparin
bind
protein
higher
valu
often
short
heparin
bind
sequenc
identifi
among
set
heparin
bind
protein
basic
amino
acid
within
region
high
similar
identifi
arginin
blue
lysin
red
histidin
green
aa
amino
acid
number
aa
amino
acid
ident
hbp
rel
frequenc
sequenc
among
heparin
bind
protein
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
tabl
tabl
predict
heparin
bind
domain
rbd
amino
acid
sequenc
number
normal
count
similar
short
heparin
bind
sequenc
rbd
found
librari
heparin
bind
protein
addit
tabl
also
contain
align
sequenc
similar
virus
sarscov
relat
bat
virus
predict
heparin
bind
region
shown
yellow
variat
within
region
relat
virus
highlight
red
human
human
human
human
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
p
n
n
l
c
p
f
g
e
v
f
n
f
p
v
w
e
r
k
r
bat
sarscovrel
p
n
n
l
c
p
f
g
e
v
f
n
k
f
p
v
w
e
r
k
k
bat
sarscovrel
p
n
n
l
c
p
f
g
e
v
f
n
f
p
v
w
e
r
k
r
shuman
n
c
v
v
l
n
f
f
k
c
g
v
p
k
l
n
bat
n
c
v
v
l
n
f
f
k
c
g
v
p
k
l
n
human
sarscov
n
c
v
v
l
n
f
f
k
c
g
v
k
l
n
bat
sarscovrel
n
c
v
v
l
n
f
f
f
k
c
g
v
k
l
n
bat
sarscovrel
n
c
v
v
l
n
f
f
k
c
g
v
k
l
n
l
c
f
n
v
f
v
r
g
e
v
r
q
p
g
q
g
k
bat
l
c
f
n
v
f
v
g
e
v
r
q
p
g
q
g
k
human
sarscov
l
c
f
n
v
f
v
v
k
g
v
r
q
p
g
q
g
v
bat
sarscovrel
l
c
f
n
v
f
v
v
k
g
v
r
q
p
g
q
g
v
bat
sarscovrel
l
c
f
n
v
f
v
v
k
g
v
r
q
p
g
q
g
v
n
k
l
p
f
g
c
v
w
n
n
n
l
k
v
g
g
n
bat
n
k
l
p
f
g
c
v
w
n
k
h
k
e
g
g
n
f
human
sarscov
n
k
l
p
f
g
c
v
l
w
n
r
n
g
n
bat
sarscovrel
n
k
l
p
f
g
c
v
l
w
n
r
n
g
n
bat
sarscovrel
n
k
l
p
f
l
g
c
v
l
w
n
n
k
g
n
yhuman
n
l
r
l
f
r
k
n
l
k
p
f
e
r
e
q
g
p
bat
n
l
r
l
f
r
k
n
l
k
p
f
e
r
e
q
g
k
p
human
sarscov
n
k
r
l
r
h
g
k
l
r
p
f
e
r
n
v
p
f
p
g
k
p
bat
sarscovrel
n
k
r
l
r
h
g
k
l
r
p
f
e
r
n
v
p
f
p
g
k
p
bat
sarscovrel
n
l
r
w
v
r
r
k
l
n
p
e
r
l
n
p
g
g
q
sc
n
g
v
e
g
f
n
c
f
p
l
q
g
f
q
p
n
g
v
g
q
p
r
bat
c
n
g
q
g
l
n
c
p
l
r
g
f
p
g
v
g
h
q
p
r
c
p
p
f
n
c
w
p
l
n
g
f
f
n
g
g
q
p
r
bat
sarscovrel
c
p
p
l
n
c
w
p
l
n
g
f
g
g
q
p
r
bat
sarscovrel
c
g
p
n
c
n
p
l
r
p
g
f
f
g
v
g
h
q
p
rv
v
v
l
f
e
l
l
h
p
v
c
g
p
k
k
n
l
v
k
n
k
c
v
bat
v
v
v
l
f
e
l
l
n
p
v
c
g
p
k
k
n
l
v
k
n
k
c
v
v
v
v
l
f
e
l
l
n
p
v
c
g
p
k
l
l
k
n
q
c
v
bat
sarscovrel
v
v
v
l
f
e
l
l
n
p
v
c
g
p
k
l
l
k
n
q
c
v
bat
sarscovrel
v
v
v
l
f
e
l
l
n
p
v
c
g
p
k
l
l
k
n
q
c
vn
f
n
f
n
g
l
g
g
v
l
e
n
k
k
f
l
p
f
q
q
f
g
r
bat
n
f
n
f
n
g
l
g
g
v
l
e
n
k
k
f
l
p
f
q
q
f
g
r
copyright
holder
preprint
version
post
april
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
